Key Stats for CVS Health Stock
- This Week Performance: +4%
- 52-Week Range: $58.4 to $85.2
- Current Price: $79.9
What Happened?
CVS Health (CVS) has transformed from a managed-care cautionary tale into a verified turnaround, with shares trading at $79.90 after rising roughly 77% throughout 2025.
On February 10, Q4 earnings delivered a direct flashpoint, with adjusted EPS of $1.1 beating the $1.0 consensus estimate while revenue of $105.7 billion cleared the $103.6 billion Wall Street forecast.
The engine powering this beat was CVS Pharmacy, where same-store prescription volumes surged nearly 10%, amplified by 9 million new patients absorbed from the Rite Aid acquisition.
Beyond the numbers, the market is actively re-rating CVS from a struggling insurance conglomerate into a diversified, integrated health platform with durable, multi-segment earnings power.
Chief Financial Officer Brian Newman stated on the Q4 earnings call that “we put out realistic targets and we try to deliver or exceed on expectations,” reflecting a full-year adjusted EPS of $6.75 that exceeded initial guidance by roughly 15%.
Further reinforcing conviction, Mubadala Investment Co raised its CVS stake by 17.3% to 149,769 shares as of December 31, while RBC Capital Markets maintained an Outperform rating with a $93 price target.
Looking ahead, CVS’s 2026 adjusted EPS guidance of $7.0 to $7.2, supported by $400 billion in projected revenue, positions it as the most structurally resilient integrated health company competing over the next three to five years.
Wall Street’s Take on CVS Health Stock
CVS’s Q4 earnings beat and reaffirmed 2026 guidance of $7.0–$7.2 adjusted EPS directly confirms the turnaround is no longer speculative.
Fundamentally, revenue grew 7.8% in 2025 to $402.1 billion while normalized EPS surged 24.5%, signaling genuine earnings acceleration after a brutal 2024 collapse.
Currently, 17 analysts rate CVS a Buy and 6 rate it Outperform, with a mean price target of $96.5, implying 20.8% upside from $79.9.
Notably, the analyst target range spans $79.0 to $138.0, where the high end requires sustained Medicare margin recovery and the low end prices in continued reimbursement pressure.
What Does the Valuation Model Say?
TIKR’s mid-case model targets $124.0 by December 2030, delivering a 55.2% total return at a 9.5% IRR from today’s $79.9.
The market prices CVS at roughly 11x forward earnings, yet EPS is forecast to grow 9.5% annually through 2031.
That 11x multiple severely undervalues a business generating $10.6 billion in annual operating cash flow.
Management’s “Say-Do ratio” philosophy, backed by 15% EPS outperformance in 2025, signals this is a mispriced compounder, not a value trap.
However, if 2027 Medicare Advantage rates remain inadequate, Aetna’s margin recovery timeline extends, threatening the $7.0 floor of 2026 EPS guidance.
Watch the final 2027 Medicare Advantage rate notice from CMS, the single data point that confirms or breaks the Aetna margin trajectory.
CVS is undervalued at 11x earnings with accelerating EPS growth; watch the CMS rate decision to confirm the thesis.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze X stock on TIKR for Free →
